Details for Patent: 8,389,472
✉ Email this page to a colleague
Title: | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
Abstract: | The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases. |
Inventor(s): | Baron; Alain D. (San Diego, CA), Kim; Dennis (San Diego, CA), Maggs; David G. (San Diego, CA), Wintle; Matthew (San Diego, CA) |
Assignee: | Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE) |
Filing Date: | Aug 21, 2006 |
Application Number: | 12/063,712 |
Claims: | 1. A method for treating nonalcoholic steatohepatitis in a human in need thereof comprising subcutaneously administering to the human a therapeutically effective amount of exendin-4 to treat the nonalcoholic steatohepatitis in the human. 2. The method of claim 1, further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof. 3. A method for treating nonalcoholic steatohepatitis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of exendin-4 to treat the nonalcoholic steatohepatitis in the subject. 4. The method of claim 3, wherein the therapeutically effective amount is an amount that maintains an average plasma concentration of exendin-4 of at least 10 pg/ml for at least 12 hours. 5. The method of claim 3, wherein the exendin-4 is parenterally administered to the subject. 6. The method of claim 3, wherein the subject is a human. 7. The method of claim 3, wherein the exendin-4 is administered to the subject by subcutaneous injection. 8. The method of claim 3, further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof. 9. A method for treating nonalcoholic fatty liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of exendin-4 to treat the nonalcoholic fatty liver disease in the subject. 10. The method of claim 9, wherein the therapeutically effective amount is an amount that maintains an average plasma concentration of exendin-4 of at least 10 pg/ml for at least 12 hours. 11. The method of claim 9, wherein the exendin-4 is parenterally administered to the subject. 12. The method of claim 9, wherein the subject is a human. 13. The method of claim 9, wherein the exendin-4 is administered to the subject by subcutaneous injection. 14. The method of claim 9, further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof. 15. A method for treating nonalcoholic fatty liver disease in a human in need thereof comprising subcutaneously administering to the human a therapeutically effective amount of exendin-4 to treat the nonalcoholic fatty liver disease in the human. 16. The method of claim 15, further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof. |